Navigation Links
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:2/10/2011

SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Optimer. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. is acting as the sole book-running manager for the proposed offering and Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC are acting as co-managers for the proposed offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Optimer Pharmaceuticals, Inc.Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the proposed public offering of securities by Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to market conditions and the satisfaction of customary closing conditions, and other risks detailed in Optimer's filings with the SEC.  All forward-looking statements are qualified in their entirety by this cautionary statement, and Optimer undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
2. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
3. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
4. Optimer Pharmaceuticals Announces Key Additions to Management Team
5. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
6. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... SAN FRANCISCO and ORLANDO, Fla. ... (Nasdaq: NKTR ) today announced that positive ... NKTR-214, in patients with renal cell carcinoma (RCC) were ... immuno-stimulatory therapy designed to expand specific cancer-fighting T cells ... tumor micro-environment and increase expression of PD-1 on these ...
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Researchers at ... thyroid cancer, as well as a marker that may predict response to a particular ... many other types of cancer as well. The new findings were published in Proceedings ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies ... by for a visit this week at HIMSS 2017 Conference & Exhibition. The ... the globe. Sensogram will be featured in the conference’s Connected Health Experience section, ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's ... building. A topping out ceremony on Friday marked the halfway point of construction and ... open in Fall 2018, will serve as a center for innovation aimed at finding ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
Breaking Medicine News(10 mins):